Cortexyme Inc CRTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 07/30/21 EDT
56.51UNCH (UNCH)
Volume
4,497
Close
56.51quote price arrow up+0.48 (+0.86%)
Volume
106,467
52 week range
26.66 - 66.13

...

Loading . . .
  • Open55.06
  • Day High58.20
  • Day Low54.24
  • Prev Close56.03
  • 52 Week High66.13
  • 52 Week High Date07/23/21
  • 52 Week Low26.66
  • 52 Week Low Date12/29/20

Key Stats

  • Market Cap1.672B
  • Shares Out29.59M
  • 10 Day Average Volume0.18M
  • Dividend-
  • Dividend Yield-
  • Beta0.77
  • YTD % Change103.42

KEY STATS

  • Open55.06
  • Day High58.20
  • Day Low54.24
  • Prev Close56.03
  • 52 Week High66.13
  • 52 Week High Date07/23/21
  • 52 Week Low26.66
  • 52 Week Low Date12/29/20
  • Market Cap1.672B
  • Shares Out29.59M
  • 10 Day Average Volume0.18M
  • Dividend-
  • Dividend Yield-
  • Beta0.77
  • YTD % Change103.42

RATIOS/PROFITABILITY

  • EPS (TTM)-2.81
  • P/E (TTM)-20.14
  • Fwd P/E (NTM)-17.00
  • EBITDA (MRQ)-84.013M
  • ROE (MRQ)-44.19%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/16/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cortexyme Inc

There is no recent news for this security.

Profile

MORE
Cortexyme, Inc. is a clinical stage biopharmaceutical company. The Company is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The Company is focused on an infectious pathogen tied to neurodegeneration and chronic inflammation in humans and animal models. The Company's lead drug candidate, COR388, is an orally administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer's...
Casey Lynch
Chairman
Christopher Lowe
Chief Financial Officer
Leslie Holsinger Ph.D.
Executive Vice President
Address
269 E Grand Ave
South San Francisco, CA
94080-4804
United States

Top Peers

SYMBOLLASTCHG%CHG
RUBY
Rubius Therapeutics Inc
21.49-1.31-5.75%
AXSM
Axsome Therapeutics Inc
48.59-1.98-3.92%
ZNTL
Zentalis Pharmaceuticals Inc
53.21-1.41-2.58%
ADCT
ADC Therapeutics SA
21.04-0.15-0.71%
INO
Inovio Pharmaceuticals Inc
8.40-0.10-1.18%